Aug 21 (Reuters) - Vanda Pharmaceuticals Inc VNDA.O:
VANDA SEEKS FDA COMMISSIONER REVIEW OF OUTGOING CDER DIRECTOR'S DECISION TO UPHOLD APPROVAL OF TWO GENERIC VERSIONS OF HETLIOZ®
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.